Tuesday, June 3, 2025
  • Login
Euro Times
No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology
Euro Times
No Result
View All Result

An experimental Alzheimer’s drug could be approved next year. But it comes with risks : NPR

by Jon Hamilton
December 7, 2022
in Health
Reading Time: 3 mins read
A A
0
Home Health
Share on FacebookShare on Twitter


Researchers say the experimental Alzheimer’s drug Lecanemab represents an important advance and is likely to get FDA approval in 2023, despite some safety concerns.



STEVE INSKEEP, HOST:

An experimental drug is raising hope for the treatment of Alzheimer’s disease, although it does come with some risks. So NPR’s Jon Hamilton looked at the evidence.

JON HAMILTON, BYLINE: The drug, called lecanemab, only slows down Alzheimer’s a bit. But it dominated last week’s Clinical Trials on Alzheimer’s Disease meeting in San Francisco. Dr. Eric Reiman was there. He’s the executive director of Banner Alzheimer’s Institute in Phoenix.

ERIC REIMAN: There was a feeling of elation that this was a milestone in the fight against Alzheimer’s disease and very important.

HAMILTON: A study of nearly 1,800 people in the early stages of Alzheimer’s found that lecanemab slowed down declines in memory and thinking by 27%. Reiman says that’s a modest but meaningful benefit from the drug.

REIMAN: It had effects on a range of cognitive and functional measurements that are important to families and family caregivers. But clearly, a treatment by itself that is not going to stop the progression of the disease.

HAMILTON: Lecanemab contains antibodies designed to remove a substance called amyloid from the brain. That makes it similar to the controversial drug Aduhelm, which received a conditional approval from the Food and Drug Administration last year. The agency acted despite conflicting evidence on whether Aduhelm slows down the disease. Reiman says the results with lecanemab are much clearer.

REIMAN: I’ll be surprised if it doesn’t get full approval.

HAMILTON: Probably sometime next year. Both Aduhelm and lecanemab have risks, including a condition known as ARIA. Dr. Sharon Cohen, medical director of the Toronto Memory Program in Canada, says when a brain scan shows ARIA, it’s a sign of either swelling or bleeding.

SHARON COHEN: This sounds very dramatic to have swelling in the brain or bleeding in the brain, and of course, nobody wants that.

HAMILTON: But Cohen says even though ARIA is common, it rarely has a big impact on patients’ health.

COHEN: What we’ve learned over time is that a very small proportion of individuals will have symptoms, and when symptoms arise, they are usually transient, mild to moderate and resolve.

HAMILTON: In rare cases, though, patients can experience brain damage or even death. Cohen says the risks of ARIA appear to be higher in people who have very high levels of amyloid in the brain or are taking blood thinners.

COHEN: There will be patients for whom this is not a good therapy.

HAMILTON: Lecanemab and other drugs that remove amyloid have another side effect that is more mysterious. They seem to cause the brain to shrink. And that concerns Dr. Madhav Thambisetty, a neurologist at the National Institute on Aging, a part of the National Institutes of Health.

MADHAV THAMBISETTY: What is a little worrying to me is that these drugs might be worsening the degenerative process that is associated with disease progression.

HAMILTON: Alzheimer’s itself causes the brain to shrink, a sign that neurons are dying. So Thambisetty, whose views are independent of the NIH, expected Alzheimer’s drugs to limit shrinkage rather than accelerate it.

THAMBISETTY: It’s incumbent upon drug developers and researchers to try and prove that these changes are benign and do not represent a significant adverse event.

HAMILTON: Dr. Reisa Sperling directs the Center for Alzheimer’s Research and Treatment at Brigham and Women’s Hospital in Boston. She says serious side effects are common in treating other diseases like cancer.

REISA SPERLING: Alzheimer’s is a terrible disease, and I think many patients and their physicians will be willing to take some risk. And our work is to minimize the risk.

HAMILTON: About 2 million Alzheimer’s patients in the U.S. are potential candidates for lecanemab.

Jon Hamilton, NPR News.

Copyright © 2022 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by an NPR contractor. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.



Source link

Tags: AlzheimersApproveddrugExperimentalNPRRisksyear
Previous Post

Renewables to be main source of electricity generation by 2025: IEA

Next Post

Putin Signs Law Banning Expressions of L.G.B.T.Q. Identity in Russia : worldnews

Related Posts

How Many Carbs Should You Eat Daily for Weight Loss?

How Many Carbs Should You Eat Daily for Weight Loss?

by Lindsey DeSoto, RD
June 2, 2025
0

Carbohydrates, or carbs, are a kind of macronutrient, a nutrient the physique wants in giant portions. Your physique converts carbs...

How cuts to the nation’s main mental health agency could impact Americans : NPR

How cuts to the nation’s main mental health agency could impact Americans : NPR

by Rhitu Chatterjee
June 2, 2025
0

The nation's essential psychological well being company is being dissolved, and folded into a brand new federal well being company....

Alan Christianson – Unraveling the Mysteries of Thyroid Health

Alan Christianson – Unraveling the Mysteries of Thyroid Health

by Dr. Mercola
June 1, 2025
0

Mercola proudly helps these charities and organizations. View All Charities & Organizations Extra About Mercola.com Disclaimer: The whole contents of...

What the Name Change Means for You

What the Name Change Means for You

by Suchandrima Bhowmik
May 31, 2025
0

MASH is the brand new time period for NASH. MASH stands for metabolic dysfunction–related steatohepatitis, a sort of liver illness....

Parents should talk to a doctor about COVID shots for kids, CDC says : Shots

Parents should talk to a doctor about COVID shots for kids, CDC says : Shots

by Pien Huang
May 31, 2025
0

The CDC's vaccine schedule recommends COVID vaccines for kids by way of 'shared medical decision-making.' There isn't any advice for...

The Best and Worst Way to Remove a Tick

The Best and Worst Way to Remove a Tick

by Angela Haupt
May 31, 2025
0

You most likely gained’t see a tick because it clings to a blade of grass, however it may see you....

Next Post
Putin Signs Law Banning Expressions of L.G.B.T.Q. Identity in Russia : worldnews

Putin Signs Law Banning Expressions of L.G.B.T.Q. Identity in Russia : worldnews

Alienware teases the return of its 18-inch gaming laptop

Alienware teases the return of its 18-inch gaming laptop

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Top CNN Reporter OUT After Outlet Pays Navy Vet Millions of Dollars in Defamation Settlement | The Gateway Pundit

Top CNN Reporter OUT After Outlet Pays Navy Vet Millions of Dollars in Defamation Settlement | The Gateway Pundit

June 2, 2025
Justin Sun takes center stage at Bitcoin Vegas 2025 with TRON DAO as top sponsor of Code + Country and co-host of Kraken’s Oceanic Night

Justin Sun takes center stage at Bitcoin Vegas 2025 with TRON DAO as top sponsor of Code + Country and co-host of Kraken’s Oceanic Night

June 3, 2025
Coherent Sees Growth In The Data Center Market; Exits Non-Core Businesses (NYSE:COHR)

Coherent Sees Growth In The Data Center Market; Exits Non-Core Businesses (NYSE:COHR)

June 2, 2025
Suspect charged with hate crime in attack at pro-Israeli rally in Colorado

Suspect charged with hate crime in attack at pro-Israeli rally in Colorado

June 3, 2025
Deal: Meater Plus smart thermometer drops to a record-low price

Deal: Meater Plus smart thermometer drops to a record-low price

June 2, 2025
Bitcoin Exchange Reserves Shrink By 668K BTC – Bullish Signal?

Bitcoin Exchange Reserves Shrink By 668K BTC – Bullish Signal?

June 2, 2025
Euro Times

Get the latest news and follow the coverage of Business & Financial News, Stock Market Updates, Analysis, and more from the trusted sources.

CATEGORIES

  • Business
  • Cryptocurrency
  • Finance
  • Health
  • Investing
  • Markets
  • Politics
  • Stock Market
  • Technology
  • Uncategorized
  • World

LATEST UPDATES

Top CNN Reporter OUT After Outlet Pays Navy Vet Millions of Dollars in Defamation Settlement | The Gateway Pundit

Justin Sun takes center stage at Bitcoin Vegas 2025 with TRON DAO as top sponsor of Code + Country and co-host of Kraken’s Oceanic Night

  • Disclaimer
  • Privacy Policy
  • DMCA
  • Cookie Privacy Policy
  • Terms and Conditions
  • Contact us

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

No Result
View All Result
  • Home
  • Finance
  • Business
  • World
  • Politics
  • Markets
  • Stock Market
  • Cryptocurrency
  • Investing
  • Health
  • Technology

Copyright © 2022 - Euro Times.
Euro Times is not responsible for the content of external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In